1-(3,4-二氯苯基)-5-异丙基双胍单盐酸盐 | 6001-93-0

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3,4-二氯苯基)-5-异丙基双胍单盐酸盐
• 中文别名: 氯胍相关物质F
• 英文名称: Chlorproguanil hydrochloride
• 英文别名: 1-(3,4-dichloro-phenyl)-5-isopropyl-biguanide; hydrochloride；1-(3,4-Dichlor-phenyl)-5-isopropyl-biguanid; Hydrochlorid；1-(3,4-dichlorophenyl)-5-isopropylbiguanide monohydrochloride；Chlorproguanilhydrochlorid；1-[Amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine;hydrochloride
• CAS: 6001-93-0
• 化学式: C₁₁H₁₅Cl₂N₅*ClH
• 分子量: 324.641
• InChiKey: SVJMILFDDBKCGG-UHFFFAOYSA-N

物化性质

• 熔点：
  246-247 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -1.77
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  93.4
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• WGK Germany：
  1

文献信息

• [EN] MEROPENEM DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE MÉROPÉNÈME ET LEURS UTILISATIONS
  申请人：KALA PHARMACEUTICALS INC

  公开号：WO2014144285A1

  公开（公告）日：2014-09-18

  The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles (e.g., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease (e.g., a respiratory tract infection).

  本发明提供了β-内酰胺抗生素的新型衍生物，如美罗培南。该创新化合物包括式(I)的化合物，以及其药学上可接受的盐、溶剂合物、水合物、多晶形、共晶体、互变异构体、立体异构体、同位素标记衍生物和前药。还提供了粒子（例如纳米粒子）和含有这些粒子的药物组合物，这些粒子能穿透黏液。这些创新的粒子和药物组合物可能有助于将创新的化合物输送到受试者的呼吸道。本发明还提供了使用方法和包括创新化合物、其粒子和/或药物组合物的试剂盒，用于治疗和/或预防肺部疾病（例如呼吸道感染）。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• Method For Improved Bioactivation Of Pharmaceuticals
  申请人：Clement Bernd

  公开号：US20120077876A1

  公开（公告）日：2012-03-29

  This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R 1 and R 2 are hydrogen, alkyl, or aryl radicals.

  这项发明涉及一种前药，其包含具有一般式(I)或(II)的部分结构，其中R1和R2为氢、烷基或芳基基团。
• COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION
  申请人：Temtsin Krayz Galia

  公开号：US20090098200A1

  公开（公告）日：2009-04-16

  Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.

  提供了一种组合物，其中包括一个亲脂性活性化合物，例如人类或兽医药物或营养保健品，与由两种或更多聚合物形成的聚合物基质交织在一起，其中一种聚合物是一种两性聚合物，另一种聚合物是具有不同疏水-亲水平衡的两性聚合物或亲水性聚合物，且活性亲脂性化合物具有改性的物理化学性质。该组合物在接触水性介质时形成胶体纳米分散体。
• HYDROXYLATED NEBIVOLOL METABOLITES
  申请人：O'Donnell John P.

  公开号：US20110065783A1

  公开（公告）日：2011-03-17

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化的内比洛尔代谢物在急性给药后以浓度依赖的方式增加人类内皮细胞制备的一氧化氮释放。此外，羟基化的内比洛尔代谢物，包括但不限于4-羟基-6,6′-二氟-、4-羟基-5-酚-6,6′-二氟-和4-羟基-8-苯基-6,6′-二氟-，具有在慢性给药后增加人类内皮细胞释放一氧化氮能力的能力。本发明提供了羟基化的内比洛尔代谢物和包含内比洛尔和/或至少一种内比洛尔羟基化代谢物和/或至少一种用于治疗心血管疾病的其他化合物或其药学上可接受的盐的组合物。此外，本发明提供了通过给靶向受影响的血管疾病的部位至少给予一种能够释放治疗有效量一氧化氮的内比洛尔羟基化代谢物的方法来治疗和/或预防血管疾病的方法。此外，本发明还涉及通过至少给予一种内比洛尔羟基化代谢物来治疗和/或预防偏头痛。此发明还可与代谢综合征疾病的单个治疗或联合治疗一起使用。